Related Experiment Videos
Infections in sickle cell anemia: pathogenesis and control
Insights
Children with sickle cell disease (SCD) face high infection risks due to splenic dysfunction. Current pneumococcal vaccines offer limited protection in young children with SCD, necessitating further research into effective prevention strategies.
Area of Science:
- Pediatric Immunology
- Infectious Diseases
- Hematology
Background:
- Homozygous sickle cell disease (SCD) significantly impairs splenic function, leading to profound immune deficits.
- Young children with SCD are at immense risk for severe pyogenic infections due to combined splenic dysfunction and immunologic immaturity.
Purpose of the Study:
- To evaluate the effectiveness of pneumococcal vaccines in children under five with SCD.
- To assess the antibody response to pneumococcal vaccines in young children with SCD.
- To investigate the potential of prophylactic antibiotic regimens for preventing pneumococcal sepsis in asplenic hosts.
Main Methods:
- Analysis of existing data on pneumococcal vaccine efficacy in children with SCD.
- Assessment of antipneumococcal antibody responses in children under two with SCD.
- Review of reported pneumococcal vaccine failures in children with SCD.
Main Results:
- Pneumococcal vaccines provide only modest protection in children with SCD younger than five years.
- Antipneumococcal antibody responses are poor in children with SCD under two years of age.
- All documented pneumococcal vaccine failures occurred in children under three with SCD, caused by specific pneumococcal serotypes.
Conclusions:
- Children with SCD, particularly those under five, have a high risk of severe infections due to splenic dysfunction.
- Current pneumococcal vaccines are not fully effective in preventing infections in young children with SCD.
- The efficacy of prophylactic antibiotics for preventing pneumococcal sepsis in asplenic children with SCD remains undetermined and requires rigorous scientific investigation.
Abstract:
Splenic dysfunction accounts for the greatest deficit in immune function in children with homozygous SCD. This dysfunction, coupled with the natural immunologic immaturity of all young children subjects the young child with SCD to an immense risk of severe pyogenic infections. To data, experience would suggest that pneumococcal vaccines may provide only modest protection in the child with SCD less than 5 years of age. Antipneumococcal antibody responses are poor in children less than two years of age. All reported failures of pneumococcal vaccine among children with SCD have occurred in children less than three years of age and offending pneumococci have been of groups 6 and 23. Prophylactic antibiotic regimens have yet to be submitted to rigid scientific investigation and their utility in eliminating the risk of pneumococcal sepsis in asplenic hosts is unknown.